COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Core Insights - Cogent Biosciences (COGT) has received FDA acceptance for the new drug application (NDA) for bezuclastinib, aimed at treating non-advanced systemic mastocytosis (NonAdvSM), with a decision expected by December 30, 2026 [1] - The NDA is based on the pivotal SUMMIT study, which met all primary and secondary endpoints, showing significant symptom improvement in patients [3][5] - The SUMMIT study indicated that patients experienced ongoing symptom improvement over time, suggesting lasting benefits from bezuclastinib treatment [4] Company Developments - Following the NDA announcement, Cogent Biosciences' shares rose by 4.9%, with a year-to-date increase of 0.5%, compared to the industry’s rise of 2.8% [2] - The company is also conducting a phase III study for bezuclastinib in another indication of systemic mastocytosis and plans to submit an NDA for advanced SM in the first half of 2026 [7][8] - Additionally, Cogent is developing bezuclastinib in combination with sunitinib for gastrointestinal stromal tumors (GIST), with an NDA filing expected in April [8][9] Safety and Efficacy - Bezuclastinib has demonstrated a favorable safety and tolerability profile, supporting its potential for chronic use in NonAdvSM patients [6] - The ongoing phase III studies and filings for bezuclastinib highlight the company's commitment to expanding its therapeutic applications [5]